105 Comac Street
23 articles with ReCor Medical
ReCor Medical Announces 6 Month On-Medication Results from RADIANCE-HTN SOLO Clinical Trial and the First Randomization in the RADIANCE-II Pivotal Study
ReCor Medical, Inc. announced the 6 month "on-medication" results from its RADIANCE-HTN SOLO clinical trial with simultaneous publication in Circulation, and the first randomization of patients in its RADIANCE-II pivotal trial of its Paradise® Renal Denervation System for the treatment of uncontrolled hypertension.
Otsuka Holdings Co., Ltd, Otsuka Medical Devices Co., Ltd. and ReCor Medical, Inc. ("ReCor") announce the signing of a merger agreement pursuant to which Otsuka Holdings will acquire the remaining shares in ReCor from its current holders.
Sofinnova Partners today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical.
ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise® Ultrasound Denervation System For Treatment Of Hypertension
ReCor expects to initiate enrollment in RADIANCE-II in October of this year.
ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator
ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients.
ReCor Medical announced today randomization of its 146th, and final, subject in the SOLO cohort of its RADIANCE-HTN study.
ReCor Medical Announces 1000th Enrollment and 150th Randomization in RADIANCE-HTN Hypertension Study
ReCor Medical announced progress milestones in the study of its Paradise Renal Denervation System as a potential treatment for hypertension, including the 1000th consented and the 150th randomized subjects in the RADIANCE-HTN study, and publication of a study design review in the American Heart Journal.
ReCor Medical Announces Collaboration And Investment With Otsuka Holdings For Asian Commercialization And Clinical Studies In The US And Europe
ReCor Medical Begins ACHIEVE Post-Market Study With Its Generation-2, Ultrasound-Based PARADISE Renal Denervation System
ReCor Medical Receives CE Mark for its Generation 2, Ultrasound-based PARADISE Renal Denervation System
ReCor Medical Reports 100% Responder Rate at One-Year Follow-up in Clinical Trial of Its Ultrasound-Based PARADISE Renal Denervation System for Treating Resistant Hypertension, a Major Risk Factor for Cardiovascular Disease
ReCor Medical Reports Impressive Six-Month Follow-Up Data for Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension
ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension